[1] approved in 1991 in the USA to treat patients who cannot tolerate AZT (Hellinger 1992)
[2] see Drug and Therapeutics Bulletin Vol. 35 No. 4 April 1997
[3] see Drug and Therapeutics Bulletin Vol. 35 No. 4 April 1997
[4] see Appendix 1 for a list of the countries included in each geographic region
[5] GDP figures from 1991 were used, since these were readily available. Health expenditure data were not readily available, and therefore calculations assumed that, on average, developing countries spend approximately 4% of their GDP on health (World Development Report 1993). Calculations for North America, Western Europe and Oceania were based on 1990 country-specific data reported in the World Development Report 1993. National AIDS Budgets data taken from "AIDS in the World II", eds. Mann and Tarantola 1996, and come from 1992 or 1993. See Appendix 1 for full details of GDP, Actual or Estimated Total Health Expenditure, and National AIDS Budgets.
[6] i.e. (10 000 ´ 420) ¸ 24 = 175 000
 AIDS Economics Home Page |
 ARV Treatment: Special Focus Back to Main Page |